Shionogi Inc v. Lupin Ltd

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Shionogi Inc. (Delaware)
  • Defendant: Lupin Limited (India) and Lupin Pharmaceuticals, Inc. (Florida)
  • Plaintiff's Counsel: FBT Gibbons LLP
• Case Identification: 2:26-cv-07831, D.N.J., 06/26/2026
• Venue Allegations: Venue is alleged to be proper based on Lupin Limited being a foreign corporation that may be sued in any judicial district and Lupin Pharmaceuticals, Inc. having a regular and established place of business in New Jersey. The complaint also cites defendants' previous consent to venue in the district in prior litigation.
• Core Dispute: Plaintiff alleges that Defendants' filing of an Abbreviated New Drug Application (ANDA) to market a generic version of Plaintiff's RADICAVA ORS® product constitutes an act of infringement of a patent covering an oral suspension formulation of edaravone.
• Technical Context: The technology relates to pharmaceutical formulations for treating Amyotrophic Lateral Sclerosis (ALS), specifically an oral suspension designed to improve patient convenience and adherence compared to intravenous treatments.
• Key Procedural History: This is a Hatch-Waxman action triggered by Lupin's submission of ANDA No. 219415 seeking to market a generic version of RADICAVA ORS®. The patent-in-suit, U.S. Patent No. 12,599,586, is listed in the FDA's "Orange Book" for RADICAVA ORS®. Shionogi acquired the RADICAVA ORS® assets from Tanabe Pharma Corporation on April 1, 2026. The complaint notes numerous other pending infringement actions in the district involving RADICAVA ORS® against other generic manufacturers. The patent-in-suit is subject to a terminal disclaimer.

Case Timeline

Date	Event
2018-11-02	Priority Date for '586 Patent
2022-05-12	FDA approves NDA for RADICAVA ORS®
2022-09-01	Lupin Pharmaceuticals submits FOIA request for RADICAVA ORS® approval summary
2024-03-28	FDA grants Orphan Drug Exclusivity for RADICAVA ORS®
2025-12-22	Shionogi announces agreement to acquire RADICAVA ORS® business
2026-04-01	Shionogi completes acquisition of RADICAVA ORS® assets
2026-04-14	'586 Patent issues
2026-05-12	Date of Lupin's Notice Letter regarding its ANDA filing
2026-06-26	Complaint Filing Date
2029-05-12	Orphan Drug Exclusivity for RADICAVA ORS® expires

II. Technology and Patent(s)-in-Suit Analysis

• Patent Identification: U.S. Patent No. 12,599,586, "Edaravone suspension for oral administration," issued April 14, 2026.
• The Invention Explained:
  • Problem Addressed: The patent describes the active pharmaceutical ingredient edaravone as a treatment for Amyotrophic Lateral Sclerosis (ALS), an intractable neurodegenerative disease '586 Patent, col. 1:50-53 While effective, edaravone has low solubility in water, and previously available intravenous formulations create a significant burden for patients and caregivers Compl. ¶11 '586 Patent, col. 25:5-11 Developing an oral version that is easy for ALS patients (who may have swallowing difficulties) to take and that achieves sufficient bioavailability has been a technical challenge '586 Patent, col. 1:47-61 '586 Patent, col. 25:47-53
  • The Patented Solution: The invention is an oral suspension of edaravone particles in water, using a specific dispersant to keep the particles uniformly suspended and in a solid state '586 Patent, abstract '586 Patent, col. 1:14-17 This formulation is designed to achieve bioavailability comparable to an intravenous injection but in a small oral dose, by controlling for specific parameters like particle size and dissolution rate '586 Patent, col. 8:36-49 '586 Patent, col. 9:20-29 The use of thickening agents is also described to aid administration for patients with dysphagia and to improve stability '586 Patent, col. 5:31-39
  • Technical Importance: This technology provides an oral alternative to IV-administered edaravone, which the complaint alleges is a "clinically superior option" that reduces the burden of treatment for ALS patients Compl. ¶12
• Key Claims at a Glance:
  • The complaint asserts infringement of at least independent claim 1 of the '586 Patent Compl. ¶47
  • Independent Claim 1 of the '586 Patent requires:
    • An edaravone suspension for human oral administration, comprising:
    • water;
    • edaravone particles comprising edaravone and dispersed in the water; and
    • a dispersant dispersing the edaravone particles in the water such that the dispersant maintains the edaravone particles in a solid particle state in the water,
    • wherein the edaravone suspension is prepared by a process comprising mixing the edaravone particles having a D50 particle size in a range of 10 µm to 50 µm and a D90 particle size in a range of 50 µm to 200 µm, the water and the dispersant, and the edaravone particles have a dissolution rate of 80% or more 30 minutes after a start of a dissolution test according to Dissolution Test Method 2 of Japanese Pharmacopoeia.
  • The complaint alleges infringement of "one or more claims," suggesting dependent claims may be asserted later Compl. ¶47

III. The Accused Instrumentality

• Product Identification: Lupin's proposed generic edaravone oral suspension, which is the subject of Abbreviated New Drug Application (ANDA) No. 219415 Compl. ¶2
• Functionality and Market Context: The complaint alleges that Lupin's product is a "generic copy of RADICAVA ORS®" Compl. ¶19 Compl. ¶42 It is described as a "proposed edaravone suspension, administered at a dose concentration of 105 mg/5 mL" Compl. ¶40 As an ANDA product, it is intended to be a lower-cost, therapeutically equivalent alternative to the brand-name drug, for which it identifies RADICAVA ORS® as the reference listed drug (RLD) Compl. ¶41 The filing of the ANDA itself, seeking FDA approval for commercialization before the expiration of the patent-in-suit, is the statutory act of infringement alleged in the complaint Compl. ¶46 Compl. ¶48

IV. Analysis of Infringement Allegations

No probative visual evidence provided in complaint.

The complaint alleges infringement but does not contain a detailed claim chart. The allegations are based on the premise that Lupin's ANDA product is a generic copy of RADICAVA ORS® and will therefore possess the characteristics claimed in the '586 Patent.

'586 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
An edaravone suspension for human oral administration, comprising: water; edaravone particles comprising edaravone and dispersed in the water; and a dispersant dispersing the edaravone particles in the water...	Lupin's ANDA No. 219415 seeks approval to market a "proposed edaravone suspension" intended as a "generic copy of RADICAVA ORS®," which is an oral suspension containing these components.	¶40; ¶42	col. 1:14-17
...such that the dispersant maintains the edaravone particles in a solid particle state in the water,	The complaint does not provide specific details on this function but alleges infringement of the entire claim, which includes this limitation, on information and belief.	¶47	col. 26:60-63
wherein the edaravone suspension is prepared by a process comprising mixing the edaravone particles having a D50 particle size in a range of 10 µm to 50 µm and a D90 particle size in a range of 50 µm to 200 µm...	The complaint does not contain specific allegations regarding the particle size in Lupin's product but alleges infringement of the claim containing this limitation.	¶47	col. 26:65-col. 27:2
...and the edaravone particles have a dissolution rate of 80% or more 30 minutes after a start of a dissolution test according to Dissolution Test Method 2 of Japanese Pharmacopoeia.	The complaint does not provide specific data on the dissolution rate of Lupin's product but alleges infringement based on it being a proposed generic copy required to be bioequivalent.	¶47	col. 27:3-6

• Identified Points of Contention:
  • Factual Questions: A central dispute will likely concern the specific, confidential characteristics of Lupin's proposed product. The complaint provides no direct evidence that Lupin's formulation meets the precise D50/D90 particle size ranges and the specific dissolution rate as measured by the Japanese Pharmacopoeia standard required by claim 1. These facts will be subject to discovery via Lupin's ANDA filing.
  • Scope Questions: The case may raise the question of whether achieving bioequivalence, as required for an ANDA approval, necessarily means that Lupin's product meets the specific functional limitations of the claim, such as the dissolution rate defined by a particular foreign pharmacopoeia's test method.

V. Key Claim Terms for Construction

• The Term: "dispersant"

  • Context and Importance: The identity and function of the "dispersant" are central to the claimed invention. Practitioners may focus on this term because the infringement analysis will depend on whether an excipient in Lupin's formulation meets the patent's definition of a "dispersant," including the functional requirement that it "maintains the edaravone particles in a solid particle state."
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The specification provides a list of exemplary dispersants, including polyvinyl alcohol, sucrose fatty acid ester, polysorbate, methylcellulose, and hypromellose, which could support an interpretation that the term covers a variety of substances '586 Patent, col. 4:45-47 '586 Patent, col. 5:3-6
    • Evidence for a Narrower Interpretation: The patent also defines dispersants by specific functional tests, such as exhibiting a "transmission scattering light intensity of 1% or more" or a "contact angle of 80 degrees or less" '586 Patent, col. 3:56-col. 4:2 '586 Patent, col. 4:47-56 A party could argue the term should be limited to substances that demonstrably pass these specific tests, potentially narrowing the claim's scope.

• The Term: "dissolution rate of 80% or more 30 minutes after a start of a dissolution test according to Dissolution Test Method 2 of Japanese Pharmacopoeia"

  • Context and Importance: This functional limitation defines a key performance characteristic of the claimed suspension by reference to a specific, non-U.S. standard. Its construction will be critical to determining if Lupin's product, which is measured against FDA bioequivalence standards, literally infringes.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: A patentee might argue that this term should be understood as a proxy for achieving rapid bioavailability and that any formulation bioequivalent to the RLD would necessarily meet the spirit, if not the letter, of this limitation.
    • Evidence for a Narrower Interpretation: A defendant could argue for a strict interpretation, contending that infringement requires proof that the accused product meets the 80% dissolution rate when tested under the exact conditions specified by the Japanese Pharmacopoeia, and that simply demonstrating FDA bioequivalence is insufficient.

VI. Other Allegations

• Indirect Infringement: The complaint alleges that Lupin will induce and contribute to infringement upon commercialization of its product Compl. ¶53 Prayer for Relief ¶B This allegation is based on the expectation that Lupin's product label will instruct physicians and patients to administer the drug for the treatment of ALS, thereby directing them to perform the infringing use.
• Willful Infringement: The complaint alleges willfulness, stating on information and belief that "Lupin was aware of the '586 patent prior to amending" its ANDA to challenge the patent Compl. ¶51 It further alleges that Lupin proceeded "despite an objectively high likelihood that its submission constituted infringement," seeking a finding of an exceptional case and an award of attorneys' fees Compl. ¶51 Prayer for Relief ¶E

VII. Analyst's Conclusion: Key Questions for the Case

• A key evidentiary question will be one of "characterization": Does Lupin's proposed generic formulation, as confidentially described in its ANDA, in fact meet the specific particle size (D50/D90) and dissolution rate criteria recited in claim 1? The litigation will likely depend on expert analysis of the data contained within Lupin's regulatory filing.
• A central legal question will be one of "equivalence": Can Shionogi prove that demonstrating FDA-required bioequivalence is sufficient to establish that Lupin's product meets the patent's specific functional limitations, particularly the dissolution rate defined by the Japanese Pharmacopoeia standard, or will a stricter, literal-for-literal comparison of test results be required?
• A core issue of claim construction will be the "definitional scope" of "dispersant." The case may turn on whether the term is interpreted broadly to cover a class of excipients or narrowed to only those that meet the specific functional tests detailed in the '586 patent's specification.